STOCK TITAN

[6-K] Kamada Ltd Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

For the Month of August 2025

 

Commission File Number 001-35948

 

Kamada Ltd.

(Translation of registrant’s name into English)

 

2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Israel
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F       Form 40-F

 

 

 

 

 

 

This Form 6-K is being incorporated by reference into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267 and 333-265866.

 

1

 

 

The following exhibit is attached:

 

99.1   Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 11, 2025 KAMADA LTD.
   
  By: /s/ Nir Livneh
   

Nir Livneh

Vice President General Counsel and
Corporate Secretary

 

3

 

 

EXHIBIT INDEX

 

EXHIBIT NO.   DESCRIPTION
99.1   Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas

 

4

 

Kamada Ltd

NASDAQ:KMDA

KMDA Rankings

KMDA Latest News

KMDA Latest SEC Filings

KMDA Stock Data

403.11M
31.27M
7.22%
48.71%
0.16%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Israel
Rehovot